Substance Name: Tovetumab [USAN:INN]
RN: 1243266-04-7
UNII: 2XY62K75UV
Notes
- A receptor platelet-derived growth factor alpha (PDGFRalpha) monoclonal antibody for treatment of advanced solid tumors.
- NCI: A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Anti-PDGFR alpha monoclonal antibody MEDI-575 inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation. (NCI Thesaurus)
Molecular Formula
- C6400-H9906-N1726-O2002-S54
Classification Code
- Treatment of Cancer
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Names and Synonyms
Name of Substance
- Tovetumab [USAN:INN]
Synonyms
- anti-PDGFR alpha monoclonal antibody MEDI-575
- Immunoglobulin G2, anti-(human platelet-derived growth factor receptor alpha) (human monoclonal MEDI-575 heavy chain), disulfide with human monoclonal MEDI-575 kappa-chain, dimer
- MEDI 575
- MEDI-575
- Tovetumab
- UNII-2XY62K75UV
Registry Numbers
CAS Registry Number
- 1243266-04-7
FDA UNII
- 2XY62K75UV
System Generated Number
- 1243266047